Kymera Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4)

About Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. is a clinical-stage biotechnology company listed on the NASDAQ in the United States, with its operational headquarters in Watertown, Massachusetts. Founded in 2016, the company was built around a clear scientific premise: harness targeted protein degradation (TPD) to create oral medicines for complex immune-mediated diseases. For international investors, Kymera sits in the higher-risk, higher-upside segment of biotech, combining an innovative platform with a pipeline that is still largely pre-commercial. Kymera’s business model is centered on discovering and developing small molecules that selectively degrade disease-causing proteins rather than simply blocking them. That distinction matters because it opens the door to drugging pathways that are often difficult to address with conventional therapeutics. The company’s strategic focus is immunology, where it is building a portfolio around oral degraders of STAT6, IRF5 and CDK2. Its lead asset, KT-621, is described as the first STAT6-directed degrader to enter clinical evaluation and is being developed across type 2 inflammatory diseases such as atopic dermatitis, asthma and related conditions. KT-579, an oral IRF5 degrader, is also in clinical development, with healthy-volunteer data expected in the second half of 2026. In parallel, KT-200, a CDK2 molecular glue degrader, became a major value-driver in April 2026 when Gilead exercised its option to exclusively license the program. From a competitive standpoint, Kymera occupies an interesting niche in a crowded biopharmaceutical landscape. Large pharma companies dominate approved immunology markets, but Kymera aims to differentiate through its proprietary discovery engine, oral dosing convenience and ability to generate assets that can be advanced internally or partnered. Management says the company has been able to advance at least one new program into clinical testing every year since founding, suggesting disciplined execution and a productive R&D engine. Recent developments have been important for validating the platform. In 2025 and 2026, Kymera reported positive clinical data for KT-621, expanded its BROADEN2 phase 2b study to include adolescents, continued advancing KT-579, and secured additional economic value from its Gilead collaboration. Its 2025 annual report also indicated a substantial cash position, supporting near-term funding needs, while reminding investors that the company remains unprofitable and exposed to standard biotech risks such as clinical setbacks and potential dilution. Overall, Kymera is a science-led NASDAQ-listed biotech in the United States with a differentiated targeted degradation platform and a pipeline that could create meaningful long-term value if clinical execution continues to improve.